A. Kondic

发表

State-of-the-Art Pharmacometric Models in Osteoporosis

T. Post, Khamir Mehta, T. Kerbusch, 2014 .

Immunogenicity of pembrolizumab in patients with advanced tumors

K. Mayawala, L. Jain, D. D. de Alwis, 2019, Journal of Immunotherapy for Cancer.

Mathematical models for the effect of anti-vascular endothelial growth factor on visual acuity

D. A. Edwards, B. Emerick, M. Zyskin, 2020, Journal of Mathematical Biology.

Evaluation of dosing strategy for pembrolizumab for oncology indications

D. D. de Alwis, J. Stone, T. Freshwater, 2017, Journal of Immunotherapy for Cancer.

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

H. Hirsch, M. Ayers, A. Loboda, 2014, PloS one.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Jiang Liu, P. Keegan, M. Chatterjee, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

J. Riess, V. Sinha, K. Mayawala, 2018, Clinical Cancer Research.

Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response

Manash S. Chatterjee, Jiang Liu, P. Keegan, 2017, Journal of Pharmacokinetics and Pharmacodynamics.

Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.

M. Vugt, F. Aarle, T. Freshwater, 2016 .

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.

Ramesh Sarangapani, Henning Schmidt, R. Sarangapani, 2014, American journal of physiology. Regulatory, integrative and comparative physiology.

Navigating Between Right, Wrong, and Relevant: The Use of Mathematical Modeling in Preclinical Decision Making

Jangir Selimkhanov, B. Schoeberl, J. Harrold, 2022, Frontiers in Pharmacology.

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

J. Stone, J. Elassaiss-Schaap, T. Freshwater, 2016, CPT: pharmacometrics & systems pharmacology.

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.

R. Sarangapani, M. Rodrigo, R. Webb, 2014, American journal of physiology. Regulatory, integrative and comparative physiology.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Manash S. Chatterjee, E. Felip, M. Hellmann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.

A. Ribas, F. Hodi, C. Blank, 2015 .